Pharmacological characterization of lysophosphatidic acid-induced pain with clinically relevant neuropathic pain drugs

European Journal of Pain : EJP
K OgawaA Kato

Abstract

Lysophosphatidic acid (LPA), an initiator of neuropathic pain, causes allodynia. However, few studies have evaluated the pharmacological profile of LPA-induced pain. In this study, a LPA-induced pain model was developed and pharmacologically characterized with clinically relevant drugs used for neuropathic pain, including antiepileptics, non-steroidal anti-inflammatory agents, analgesics, local anaesthetics/antiarrhythmics and antidepressants. Gabapentin (1-30 mg/kg, p.o.) significantly reversed LPA-induced allodynia, but neither indomethacin (30 mg/kg, p.o.) nor morphine (0.3-3 mg/kg, s.c.) did, which indicates that LPA-induced pain consists mostly of neuropathic rather than inflammatory pain. Both pregabalin (0.3-10 mg/kg, p.o.) and ω-CgTX MVIIA (0.01-0.03 μg/mouse, i.t.) completely reversed LPA-induced allodynia in a dose-dependent manner. Lidocaine (1-30 mg/kg, s.c.), mexiletine (1-30 mg/kg, p.o.) and carbamazepine (10-100 mg/kg, p.o.) significantly ameliorated LPA-induced allodynia dose dependently. Milnacipran (30 mg/kg, i.p.) produced no significant analgesic effect in LPA-induced allodynia. In LPA-injected mice, expression of the α2δ1 subunit of the voltage-gated calcium channel (VGCC) was increased in the dorsal root g...Continue Reading

References

Jul 20, 2001·British Journal of Anaesthesia·D BridgesA S Rice
May 6, 2003·The Journal of Pharmacology and Experimental Therapeutics·Yukinori NagakuraTokio Yamaguchi
Jan 14, 2004·The Journal of Pharmacology and Experimental Therapeutics·Md Harunor RashidHiroshi Ueda
Jun 15, 2004·Nature Medicine·Makoto InoueHiroshi Ueda
Jun 25, 2004·Journal of Pharmacological Sciences·Akiko SakaueHideki Ono
Jan 24, 2006·The Journal of Pain : Official Journal of the American Pain Society·John D Markman, Robert H Dworkin
Mar 20, 2008·Anesthesia and Analgesia·Takahiro SuzukiTakashi Mashimo
Sep 5, 2009·Journal of Pharmacological Sciences·Kazuhisa MinamiAkira Kato

❮ Previous
Next ❯

Citations

Nov 30, 2013·Progress in Lipid Research·Marco SisignanoKlaus Scholich
Sep 30, 2014·Peptides·Richard J Bodnar
Jun 6, 2015·Neuropharmacology·Matthieu RoussetPierre Charnet
Apr 10, 2016·Neuropharmacology·María VelascoGraham K Sheridan
Jan 2, 2014·The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology·Amarjot Kaur GrewalNirmal Singh
May 30, 2013·British Journal of Pharmacology·A JayamanneC W Vaughan
Mar 20, 2021·European Journal of Pharmacology·Shiori KawasakiMasahide Fujita

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.